SynthesisBMC pulmonary medicine2021
Isolated pulmonary mucormycosis in an immunocompetent patient: a case report and systematic review of the literature.
Synthesis in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Fatal Pulmonary Mucormycosis in a Renal Transplant Recipient: A Missed Opportunistic Infection.Cureus · 2026Article
- Transection of the Right Intermediate Bronchus Caused byInfection and drug resistance · 2026Article
- Aggressive Management of Pulmonary Mucormycosis Necrotizing Fasciitis in a Post-Liver Transplant Patient.Cureus · 2025Article
- Article
- Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review.Journal of fungi (Basel, Switzerland) · 2024Article
- AlternativeFrontiers in cellular and infection microbiology · 2024Review
- Pulmonary mucormycosis in an immunocompetent young female: a case report and literature review.Frontiers in medicine · 2024Article
- Fatal Tracheal and Bronchial Destruction Due to Pulmonary Mucormycosis in a 20-Year-Old with Diabetic Ketoacidosis.Infection and drug resistance · 2024Article
- A case of pulmonary co-infection withRespiratory medicine case reports · 2024Article
- Social determinants of health as drivers of fungal disease.EClinicalMedicine · 2023Review
- Chronic pulmonary mucormycosis caused by rhizopus microsporus mimics lung carcinoma in an immunocompetent adult: A case report.World journal of clinical cases · 2023Article
- Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.European journal of medicinal chemistry · 2023Review
- A case of pulmonary mucormycosis presented with cardiac arrest.World journal of emergency medicine · 2023Article
- Article
- Article
- Mucormycosis in COVID-19 Patients: A Case-Control Study.Microorganisms · 2022Article
- Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.Molecular biology reports · 2022Review
- Pulmonary mucormycosis after renal transplantation: A case report and a literature review.Annals of medicine and surgery (2012) · 2022Article
- Rare Presentation of an Uncommon Disease.Tuberculosis and respiratory diseases · 2022Article
- Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary mucormycosis caused by Mucorales is a highly lethal invasive fungal infection usually found in immunocompromised patients. Isolated pulmonary mucormycosis in immunocompetent patients is very rare. Here, we present a case of a 32-year-old male who developed pulmonary mucormycosis without any known immunodeficiency. CASE PRESENTATION: The patient presented to our hospital because of cough and chest pain along with blood in the sputum. He was first treated for community-acquired pneumonia until bronchoalveolar lavage fluid culture confirmed the growth of Absidia. His symptoms were relieved with the use of amphotericin B, and he eventually recovered. We also provide a systematic review of relevant literature to summarize the characteristics of pulmonary mucormycosis in immunocompetent patients.
conclusionsPulmonary mucormycosis has variable clinical presentations and is difficult to identify. Due to its high fatality rate, clinicians should make judgements regarding suspected cases correctly and in a timely manner to avoid misdiagnosis and delayed treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.